An expanding role for osimertinib for the treatment of ErbB family driven NSCLC

The discovery that a subset of non-small cell lung cancers (NSCLC) were dependent upon reoccurring activating EGFR (ErbB1) mutations (1-4), primarily deletions of exon 19 or an activating point mutation, L858R, ushered in the era of targeted therapies for lung cancer.